Colistin heteroresistance in Enterobacter cloacae is associated with cross-resistance to the host antimicrobial lysozyme

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5594-5597

  Napier, Brooke A ^a,b   Band, Victor ^a   Burd, Eileen M ^a   Weiss, David S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL LYSOZYME; COLISTIN; LYSOZYME; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COLISTIN HETERORESISTANT ENTEROBACTER CLOACAE; CROSS RESISTANCE; ENTEROBACTER CLOACAE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER CLOACAE; IMMUNITY, INNATE; MICROBIAL SENSITIVITY TESTS; MURAMIDASE;

EID: 84906097341     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02432-14     Document Type: Article

References (22)

1. CDC. 16 September 2013, posting date. Antibiotic resistance threats in the United States. CDC, Atlanta, GA. http://www.cdc.gov/drugresistance/threat- report-2013/.
2. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357. (Pubitemid 350168315)
3. Tamayo M, Santiso R, Otero F, Bou G, Lepe JA, McConnell MJ, Cisneros JM, Gosálvez J, Fernández JL. 2013. Rapid determination of colistin resistance in clinical strains of Acinetobacter baumannii by use of the micromax assay. J. Clin. Microbiol. 51:3675-3682. http://dx.doi.org/10.1128/JCM.01787- 13.
4. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti. Infect. Ther. 10:917-934. http://dx.doi.org/10.1586/eri.12.78.
5. Fidai S, Farmer SW, Hancock RE. 1997. Interaction of cationic peptides with bacterial membranes. Methods Mol. Biol. 78:187-204.
6. Düring K, Porsch P, Mahn A, Brinkmann O, Gieffers W. 1999. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 449:93-100. http://dx.doi.org/10.1016/S0014-5793(99)00405-6. (Pubitemid 29192885)
7. Ibrahim HR, Thomas U, Pellegrini A. 2001. A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J. Biol. Chem. 276:43767-43774. http://dx.doi.org/10.1074/jbc.M106317200.
8. Laible NJ, Germaine GR. 1985. Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and Streptococcus faecalis: inhibition by chitin oligosaccharides. Infect. Immun. 48:720-728. (Pubitemid 15021320)
9. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. http://dx.doi.org/10.1128/AAC.00103- 06. (Pubitemid 44396396)
10. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52:351-352. http://dx.doi.org/10.1128/AAC.00766-07.
11. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 66:946-947. http://dx.doi.org/10.1093/jac/dkr007.
12. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. 2008. Heteroresistance: a concern of increasing clinical significance? Clin. Microbiol. Infect. 14:101-104. http://dx.doi.org/10.1111/j.1469-0691.2007.01912. x.
13. Deresinski S. 2009. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 199:605-609. http://dx.doi.org/10.1086/ 596630.
14. Morand B, Mühlemann K. 2007. Heteroresistance to penicillin in Streptococcus pneumoniae. Proc. Natl. Acad. Sci. U. S. A. 104:14098-14103. http://dx.doi.org/10.1073/pnas.0702377104. (Pubitemid 350003341)
15. Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen PH. 2007. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 51:3726-3730. http://dx.doi.org/10.1128/AAC.01406-06. (Pubitemid 47519365)
16. Gaston MA. 1988. Enterobacter: an emerging nosocomial pathogen. J. Hosp. Infect. 11:197-208. http://dx.doi.org/10.1016/0195-6701(88)90098-9.
17. John JF, Sharbaugh RJ, Bannister ER. 1982. Enterobacter cloacae: bacteremia, epidemiology, and antibiotic resistance. Rev. Infect. Dis. 4:13-28. http://dx.doi.org/10.1093/clinids/4.1.13.
18. Keller R, Pedroso MZ, Ritchmann R, Silva RM. 1998. Occurrence of virulence-associated properties in Enterobacter cloacae. Infect. Immun. 66:645-649. (Pubitemid 28074207)
19. Sanders WE, Sanders CC. 1997. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin. Microbiol. Rev. 10:220-241. (Pubitemid 27196669)
20. Mezzatesta ML, Gona F, Stefani S. 2012. Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance. Future Microbiol. 7:887-902. http://dx.doi.org/10.2217/fmb.12.61.
21. Stock I, Grüger T, Wiedemann B. 2001. Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex. Int. J. Antimicrob. Agents 18:537-545. http://dx.doi.org/10.1016/S0924-8579(01)00463-0. (Pubitemid 33152747)
22. Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS. 2013. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. mBio 4(3):e00021-13. http://dx.doi.org/10.1128/mBio.00021-13.